We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 427

FCA refuses to stay injunction order

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Janssen and Abbvie were involved in a patent infringement action. Abbvie was successful in its claim for infringement, and the patent was held to be

The Federal Court finds two generic company's allegations to be unjustified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Two PM(NOC) decisions relating to the same patent were recently released by the Federal Court. In both cases, the applications were allowed

Patent held invalid for not meeting promise of improved therapeutic profile

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 10 2014

Apotex was successful in the previous NOC Proceeding. It came to market with an esomeprazole product. AstraZeneca sued for patent infringement and

Still safe the experimental use exception to anticipation

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • July 10 2014

Canada's laws provide a one-year grace period for public disclosures by the applicant (or by a person who obtained knowledge of an invention from the

Pharma in brief - Federal Court of Appeal overturns Federal Court decision and dismisses application for prohibition order

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 2 2014

Pharmascience Inc. (Pharmascience) appealed from the decision of Justice O’Keefe of the Federal Court (reported as AstraZeneca Canada Inc. v

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

PM(NOC) proceedings: Apotex defeats Bayer’s Canadian patent on oral contraceptive YAZ

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • June 19 2014

On June 4, 2014 Justice Roger Hughes of the Federal Court released his public reasons for dismissing Bayer's prohibition application against Apotex

Federal court dismisses notion that patents should be given only one interpretation for all purposes

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • June 19 2014

In a pair of simultaneously released decisions on June 13, 2014, Justice O'Reilly allowed Allergan's applications (the "Applications") prohibiting

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • June 19 2014

"Personalized medicine," in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs and preferences

Permanent injunction granted despite patentee not having a product that practiced the claims of the patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 18 2014

On May 22, 2014, the Federal Court of Canada issued an injunction curtailing Janssen Inc.’s marketing of its drug ustekinumab (STELARA) in ongoing